本文選題：FOXC1 + E-Cadherin　； 參考：《青島大學(xué)》2017年碩士論文

【摘要】：目的:探討叉頭框蛋白C1(FOXC1)基因與E-鈣粘附蛋白(E-Cadherin)基因在胃癌組織、癌旁組織中的表達(dá)情況,兩者之間是否具有統(tǒng)計(jì)學(xué)差異;并就其表達(dá)與胃癌病人臨床病理特征的關(guān)系進(jìn)行分析,為胃癌患者的臨床診斷、治療、預(yù)后提供可能的理論依據(jù)。方法:選取2014年3月至2016年6月青島大學(xué)附屬醫(yī)院急診普外科住院的胃癌手術(shù)病人102例(均以病理檢查明確診斷),剔除不符合納入標(biāo)準(zhǔn)者3例(術(shù)前行其他治療者2例;同時(shí)合并有其他臟器腫瘤者1例),剩余99例。分別取胃癌病人手術(shù)切除后的癌旁組織(切除距腫瘤邊緣6cm)及胃癌組織制作的病理石蠟切片(以上胃癌組織及癌旁組織的選取均經(jīng)病理科老師在顯微鏡下協(xié)助證實(shí)),選取的胃癌組織標(biāo)本作為胃癌組,癌旁組織作為癌旁組。使用免疫組織化學(xué)(非生物素二步法)檢測胃癌組及癌旁組中FOXC1基因與E-Cadherin基因的表達(dá)情況,然后分析其在統(tǒng)計(jì)學(xué)上有無差異性。然后根據(jù)胃癌病人的年齡、性別、有無淋巴結(jié)轉(zhuǎn)移、浸潤深度、TNM分期、腫瘤分化程度等臨床指標(biāo)進(jìn)行分組比較,探討FOXC1基因及E-Cadherin基因的表達(dá)與胃癌病人臨床病理特征之間的關(guān)系。結(jié)果:(1)FOXC1基因在胃癌組織、癌旁組織中的陽性表達(dá)率分別為73.74%、44.44%,FOXC1基因在胃癌組織、癌旁組織中的表達(dá)存在明顯統(tǒng)計(jì)學(xué)差異(P0.05)。(2)E-Cadherin基因在胃癌組織及癌旁組織中的陽性表達(dá)率分別為29.29%、73.74%,E-Cadherin基因在胃癌組織和癌旁組織中的表達(dá)存在明顯的統(tǒng)計(jì)學(xué)差異(P0.05)。(3)FOXC1基因的表達(dá)與胃癌病人的性別、年齡無統(tǒng)計(jì)學(xué)差異(P0.05),FOXC1基因的表達(dá)與腫瘤的組織分型、腫瘤TNM分期、組織浸潤深度、有無淋巴結(jié)轉(zhuǎn)移存在明顯統(tǒng)計(jì)學(xué)差異(P0.05);E-Cadherin基因的表達(dá)與胃癌病人的年齡、性別無明顯的統(tǒng)計(jì)學(xué)差異(P0.05),與腫瘤的組織分型、腫瘤的TNM分期、有無淋巴結(jié)轉(zhuǎn)移有統(tǒng)計(jì)學(xué)差異(P0.05);FOXC1基因與E-Cadherin基因在胃癌組織中的表達(dá)存在負(fù)相關(guān)性,X2值為54.31,r=-0.887,(P0.05)。FOXC1基因與E-Cadherin基因在癌旁組織中的表達(dá)存在正相關(guān)性,X2值為69.02,r=0.789,(P0.05)。結(jié)論:FOXC1及E-Cadherin基因可能參與胃癌的發(fā)生、發(fā)展過程,可能作為診斷胃癌病人臨床及預(yù)后的一項(xiàng)指標(biāo),或可能成為胃癌靶向治療的一個(gè)新靶點(diǎn)。
[Abstract]:Objective: to investigate the expression of forkhead protein C1FOXC1 gene and E-cadherin gene in gastric cancer tissues and adjacent tissues, and whether there is statistical difference between them.The relationship between its expression and clinicopathological features of gastric cancer patients was analyzed to provide possible theoretical basis for clinical diagnosis, treatment and prognosis of gastric cancer patients.Methods: 102 patients with gastric cancer were selected from March 2014 to June 2016 in emergency department of general surgery, Qingdao University affiliated Hospital (all patients were diagnosed by pathological examination, 3 cases were excluded from the inclusion criteria) (2 cases received other treatment before operation);At the same time, other organ tumors were found in 1 case and the remaining 99 cases.The paracancerous tissues (6 cm from the margin of the tumor) and the pathological paraffin sections made by the gastric cancer tissues were taken from the patients with gastric cancer after surgical resection. (the selection of the above gastric cancer tissues and the adjacent tissues were all assisted by the pathologist under the microscope.The specimens of gastric cancer were selected as gastric cancer group,Paracancerous tissue is used as the paracancerous group.The expression of FOXC1 gene and E-Cadherin gene in gastric cancer group and paracancerous group were detected by immunohistochemistry (non-biotin two-step method), and then the statistical differences were analyzed.Then according to the age, sex, lymph node metastasis, TNM stage and tumor differentiation of gastric cancer patients, the patients were grouped and compared.To investigate the relationship between the expression of FOXC1 gene and E-Cadherin gene and the clinicopathological features of gastric cancer patients.Results the positive expression rates of FOXC1 gene in gastric cancer tissues and adjacent tissues were 73.74 and 44.44, respectively.And the sex of patients with gastric cancer,There was no significant difference in age between the expression of FOXC1 gene and tumor type, TNM stage, depth of infiltration, lymph node metastasis and age of patients with gastric cancer.There was no significant statistical difference in sex (P 0.05), and there was no significant difference between sex and tumor tissue type, tumor TNM stage,Conclusion the gene of: FOXC1 and E-Cadherin may be involved in the occurrence and development of gastric cancer, and may be used as a marker for clinical diagnosis and prognosis of gastric cancer patients, or as a new target for the targeted therapy of gastric cancer.
【學(xué)位授予單位】：青島大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R735.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 徐倩;段華;汪沙;甘露;付鳳仙;湯一群;;宮腔粘連子宮內(nèi)膜組織中ArhGAP29、E-cadherin的表達(dá)及意義[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2017年01期

2 張宇龍;張國栓;范曉燕;崔專義;;進(jìn)展期胃癌Rb蛋白表達(dá)與E-cadherin及β-catenin在轉(zhuǎn)移淋巴結(jié)癌細(xì)胞中再表達(dá)的關(guān)系及臨床意義[J];河北醫(yī)藥;2016年22期

3 易世江;陳柏林;申一鳴;陳瑩;劉鵬;雷迅;;沉默F(xiàn)OXC1基因?qū)Ρ茄拾┘?xì)胞系5-8F凋亡和周期的影響[J];實(shí)用醫(yī)學(xué)雜志;2016年21期

4 康麗霞;楊秀珍;李冬霞;馮艷玲;;E-鈣粘蛋白基因甲基化在胃癌發(fā)展中的機(jī)制研究[J];中國衛(wèi)生檢驗(yàn)雜志;2016年12期

5 聶麗敏;王琳琳;劉杰;高薇;林文俐;喬麗;孫玉萍;;FOXC1蛋白在食管鱗狀細(xì)胞癌中的表達(dá)及臨床意義[J];中國老年學(xué)雜志;2016年04期

6 趙世巧;陳忠余;鄧瑋;胡仁智;陳大蘭;;eIF4E、CD44和E-cadherin在胃癌組織中的表達(dá)[J];廣東醫(yī)學(xué);2016年02期

7 符濤;季加孚;;胃癌診療的熱點(diǎn)和問題[J];中國腫瘤臨床;2016年01期

8 趙志娟;袁宏偉;賈永峰;韋玄;施琳;;骨橋蛋白對人舌鱗狀細(xì)胞癌Tca-8113細(xì)胞上皮-間質(zhì)轉(zhuǎn)化及生物學(xué)行為的影響[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2015年12期

9 陳瀟雅;余長云;張欣;;上皮間質(zhì)轉(zhuǎn)化與腫瘤轉(zhuǎn)移的研究進(jìn)展[J];中國耳鼻咽喉顱底外科雜志;2015年04期

10 金益;邵欽樹;;FOXO1基因在腫瘤中的研究進(jìn)展[J];腫瘤學(xué)雜志;2015年02期

，

本文編號：1731257